Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Dutton Update

Dutton Update

posted on Nov 10, 2008 06:33PM

http://www.duttonassociates.com/rese...

Rating: Strong Speculative Buy

11/10/2008

Patriot Scientific Confirms Rick Goerner as President/CEO; Strong Speculative Buy Reiterated

Patriot Scientific announced the confirmation of Rick Goerner as President and Chief Executive Officer. Mr. Goerner has acted as interim

President and CEO since February 29, 2008.

Since the end of February, Goerner has made great strides in transitioning Patriot Scientific to being a software-focused operating

company. The transitioning to become an operating company began in earnest with the change of management in February 2008, when

Rick Goerner became interim President and CEO. Under Goerner's management, Patriot has built up a strong experienced management

team, and begun an aggressive M&A strategy that has as its main focus companies that present opportunities in the software, secure

networking, and wireless technology sectors with secure data sharing tools emphasizing health care and government data bases. Thus far,

the M&A program includes the acquisition of CrossFlo Systems and an investment in Avot Media. Patriot Scientific has recently executed a

Memorandum of Understanding to acquire the assets of Iameter, a company whose resources will merge into Crossflo before year-end if the

transaction is finalized.

Goerner is operating with an eye toward increasing stockholder's value. To that end, Patriot Scientific has an aggressive stock buy-back

program; purchasing approximately 2.4 million shares in the quarter ended August 31, 2008, adding to the 21.6 million shares repurchased

in FY2007 and FY2008. Patriot Scientific has recently taken on a new IR firm and has added an in-house IR officer to field calls.

SUMMARY

We congratulate Goerner on the recognition by the Board of Directors and the great progress he has made in eight months. And we look

forward to the deserved recognition of Patriot Scientific's common stock. We continue to believe an investment in Patriot Scientific will bring

strong capital appreciation withminimal downside risk to investors.

We reiterate our Strong Speculative Buy Rating and our $0.55 per share price target.



Share
New Message
Please login to post a reply